ClinicalIntelPulse · Clinical Sponsor Intel

import { wrapFetchWithPayment } from "@x402/fetch";
import { privateKeyToAccount } from "viem/accounts";

const account = privateKeyToAccount(process.env.PRIVATE_KEY);
const fetchWithPay = wrapFetchWithPayment(fetch, account);

const res = await fetchWithPay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/sponsor-intel", {
  method: "GET",
});
const data = await res.json();

curl -X GET \
  "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/sponsor-intel?focus=pipeline+%7C+approvals+%7C+deals+%7C+all+%28default%3A+all%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29&sponsor=Company+name+%E2%80%94+e.g.+%22Moderna%22+%7C+%22BioNTech%22+%7C+%22Alnylam%22+%7C+%22Vertex+Pharmaceuticals%22+%7C+%22Regeneron%22" \
  -H "X-PAYMENT: <signed x402 payment>"

{
  "competitive_position": "Global leader in RNAi therapeutics. 6 approved drugs. Patent portfolio dominant through 2035+.",
  "fda_approvals": [
    {
      "approved": "2018",
      "drug": "Patisiran (Onpattro)",
      "first_in_class": true,
      "indication": "hATTR polyneuropathy",
      "type": "NDA"
    },
    {
      "approved": "2019",
      "drug": "Givosiran (Givlaari)",
      "indication": "Acute hepatic porphyria",
      "type": "NDA"
    }
  ],
  "investment_signals": {
    "near_term_catalysts": [
      "HELIOS-B ATTR-CM readout 2025",
      "ALN-APP Phase 2 for early Alzheimer's"
    ],
    "pipeline_value_estimate": "$12-18B risk-adjusted NPV",
    "risks": [
      "Pricing pressure in rare disease",
      "RNAi delivery competition from Arrowhead"
    ]
  },
  "partnership_activity": "Novartis partnership (inclisiran, cardiovascular) — $9.7B deal. Roche collaborations ongoing. Regeneron RNAi collaboration $400M+.",
  "phase3_assets": [
    {
      "completion": "2025-Q3",
      "condition": "ATTR Cardiomyopathy",
      "drug": "Vutrisiran (Amvuttra)",
      "nctId": "NCT04153149",
      "significance": "Key label expansion into ATTR-CM — $3B+ market",
      "status": "ACTIVE_NOT_RECRUITING"
    }
  ],
  "pipeline_summary": {
    "phase1_count": 8,
    "phase2_count": 9,
    "phase3_count": 6,
    "primary_therapeutic_areas": [
      "Rare genetic diseases (TTR, PH1, AHP)",
      "Cardiovascular (inclisiran)",
      "CNS (Huntington's)"
    ],
    "total_active_trials": 23
  },
  "query_summary": {
    "focus": "all",
    "sponsor": "Alnylam Pharmaceuticals"
  }
}